|

TAS6417 Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: CLN-081, Zipalertinib, zipalertinib

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • Taiho Oncology, Inc.3

Indications

  • Lung Cancer3
  • Cancer3
  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations1
  • Uncommon EGFR Mutations1
  • Early Stage Lung Cancer1

Birmingham, Alabama1 trial

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

University of Alabama at Birmingham

Phase 2

Anchorage, Alaska1 trial

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Alaska Oncology and Hematology

Phase 3

Henderson, Nevada1 trial

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Comprehensive Cancer Centers of Nevada - Henderson

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.